Recent Updates
Recently added Catalysts

Ad/PNP

Phase 2

Recurrent Head and Neck Cancer | Monoclonal antibody | Oncology |GeoVax Labs, Inc.|Last Updated: Mar 26, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment10
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03754933Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck CancerPHASE1/PHASE2 COMPLETED 10 — — Feb 1, 2019Dec 1, 2024Mar 26, 2025 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Ad/PNPBIOLOGICALAd/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
Fludarabine PhosphateDRUGFludarabine phosphate is an anticancer agent currently used for treatment of patients with chronic lymphocytic leukemia.
Unlock Study Design Details
Competitive Landscape -Head and Neck Cancer 156 trials
CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN9PHASE3Monalizumab, Cetuximab, volrustomig, Volrustomig, Cisplatin
GSK plc Sponsored ADRGSK3PHASE3Dostarlimab, Belrestotug, Nelistotug, Remzistotug, Niraparib
Merck & Co., Inc.MRK3PHASE3Pembrolizumab, Cisplatin /m^2, pembrolizumab, Cisplatin, Docetaxel
Johnson & JohnsonJNJ4PHASE3JNJ-90301900, Cetuximab, Amivantamab, Pembrolizumab, Carboplatin
Pfizer Inc.PFE6PHASE2tisotumab vedotin, pembrolizumab, carboplatin, cisplatin, Palbociclib
Regeneron Pharmaceuticals, Inc.REGN4PHASE2cemiplimab, Platinum Doublet, fianlimab, fianlimab+cemiplimab, Cemiplimab
PDS Biotechnology Corp.PDSB1PHASE3Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
Exelixis, Inc.EXEL4PHASE2Zanzalintinib, Pembrolizumab, cabozantinib, atezolizumab, Nivolumab
Merus B.V.MRUS4PHASE3Petosemtamab, Pembrolizumab, MCLA-129, Osimertinib, Chemotherapy
Bristol-Myers Squibb CompanyBMY3PHASE2Nivolumab, Relatlimab, Ipilimumab, Intratumoral Ipilimumab, BMS-986340
Bicara Therapeutics Inc.BCAX3PHASE2Ficerafusp alfa, Nivolumab, Pembrolizumab, BCA101
Gilead Sciences, Inc.GILD2PHASE2Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin
Inhibrx Biosciences, Inc.INBX2PHASE2INBRX-106, Pembrolizumab, INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab, Carboplatin AUC-5
Incyte CorporationINCY1PHASE2Retifanlimab, INCAGN02385, INCAGN02390
BioNTech SE Sponsored ADRBNTX1PHASE2BNT113, Pembrolizumab
Coherus Oncology, Inc.CHRS4PHASE2Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Docetaxel
ALX Oncology Holdings, Inc.ALXO3PHASE2evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU, ALX2004
ImmunityBio IncIBRX2PHASE2N-803 + Pembrolizumab, PD-L1 t-haNK, Cetuximab, NAI
Summit Therapeutics IncSMMT2PHASE3Ivonescimab /kg, Ligufalimab, Pembrolizumab, Ivonescimab
IO Biotech, Inc.IOBT1PHASE2IO102-IO103, Pembrolizumab KEYTRUDA
Unlock Competitive Intelligence